Abstract Decreased expression of heparan sulphate has been shown in the glomerular basement membrane of patients with overt diabetic nephropathy. Lowmolecular-weight heparin (LMWH) is a highly sulphated glycosaminoglycan with strong structural and functional similarities to heparan sulphate. In a first study, we set out to assess if LMWH could decrease the urinary albumin excretion rate (AER) in diabetic patients with overt nephropathy. Six patients entered a randomized, double-blind, placebocontrolled crossover study with treatment episodes of 1 month, separated by a 1-month wash-out. Patients self-administered prefilled syringes with either placebo or LMWH (enoxaparin 40mg/0.4ml) at bedtime. Baseline AER levels before either treatment period were similar. In contrast to placebo, AER significantly decreased from 447 (181-1102) to 295 (100-873) ug/min after 1 month treatment with LMWH (P<0.05). Compared to placebo, the effect of LMWH did not reach statistical significance in these six patients after 1 month treatment (P=0.16). Haemodynamic variables including glomerular filtration rate and filtration fraction did not change during enoxaparin treatment.
Introduction
Heparan sulphate is reckoned to provide an important structural contribution to the charge and size barrier of the glomerular basement membrane [1] . It constiCorrespondence and offprint requests to: Jouke T. Tamsma MD, Dept. of Endocrinology, University Hospital, Building 1, C4-R, PO-box 9600, 2300 RC Leiden, The Netherlands. tutes 90% of the negative charge of the GBM [2] and the resulting hydration of the membrane prevents its clogging [3] . In in-vivo studies, removal of heparan sulphate from the glomerular basement membrane resulted in albuminuria [4] .
Decreased production of heparan sulphate has been observed in mesangial and glomerular visceral epithelial cells cultured in medium containing high glucose levels [5] [6] [7] [8] . Decreased staining of heparan sulphate has been shown in the GBM of patients with overt diabetic nephropathy [9, 10] . The albuminuria observed in patients with diabetic nephropathy has been postulated to result from decreased expression of heparan sulphate [11] .
Sulphated glycosaminoglycans arrested progression of several experimental renal diseases characterized by mesangial proliferation and sclerosis [12, 13] . In streptozotocin diabetic rats, diabetic nephropathy could be prevented by treatment with sulphated glycosaminoglycans [14] , Recently a decrease of AER has been reported in patients with incipient diabetic nephropathy treated with LMWH [15] . Heparin or low-molecularweight heparins (LMWH) have been used in these studies since they are highly sulphated glycosaminoglycans with strong structural and functional resemblance to heparan sulphate [1] .
Studies with sulphated glycosaminoglycans have not been reported in type 1 diabetic patients with overt diabetic nephropathy. In this paper we report on our first experience with LMWH treatment in these patients.
Subjects and methods

Design
A randomized, double-blind, placebo-controlled crossover study was performed with treatment periods of 1 month. A crossover washout period of 1 month separated the treatment periods. End-point of the study was albumin excretion rate (AER) assessed in three timed overnight urine collections. Urine was collected with 14 days intervals before and during the treatment episodes. The last three samples of a treatment episode were collected during the last days of treatment with either placebo or LMWH. At the start and end of each treatment period renal plasma flow (RPF), glomerular filtration rate (GFR) and filtration fraction were assessed. The study protocol was approved by the local ethical committee and informed consent was obtained from all patients.
Patients
Six male insulin-dependent (type 1) diabetic patients with overt nephropathy (AER > 200 ug/min) entered the study. Mean age was 49 (range 33-60) years. Mean duration of diabetes was 29 (range 17-42) years. Renal function ranged from 70 to 137ml*min"'*1.73 m" 2 . AER ranged between 200 and 400 ug/min in three patients, and between 400 and 800 ug/min in two. In one patient it exceeded 2000 ug/min. Mean baseline AER was 435 (161-1169) ug/min. Diabetic retinopathy had previously been shown in all patients, and no signs of renal diseases other than diabetic nephropathy were observed. At each visit, after 5 min rest, blood pressure was measured three times in supine position with 2 min interval between measurements, using a random zero sphygmomanometer. Mean systolic and diastolic blood pressure was 161 (24)/83 (10) . Three patients were treated for arterial hypertension with enalaprilate and continued their medication throughout the study. The patients did not use other medication, and had no medical contraindications against the use of heparin. Fundus photography was used to exclude haemorrhage-prone retinal lesions. Before and during the study laboratory screening of kidney and liver function, and of haematological parameters including platelet counts, was performed. Furthermore, bleeding time, prothrombin and activated partial thromboplastin time, and fibrinogen levels were assessed before the start of a treatment period.
183
Statistical analysis
Values are presented as mean with SD. Albuminuria is given as geometric mean (antilog 95% confidence interval of the '"logarithms). As a consequence of the crossover design, the effect of treatment has been defined as the change of a certain parameter, i.e. AER. The effects observed during placebo were compared to the effects observed during LMWH treatment. Statistical evaluation was performed using either paired t tests or Wilcoxon's signed rank tests, depending on variable distribution. After io log transformation of AER paired t tests could be used to quantify the effect of treatment and to perform power analysis. P values of 0.05 or less were considered significant.
Results
All patients completed the study. Metabolic control did not change during the study: HbAlc 8.8 ±1.8% and 8.2+1.6% before and after the first treatment episode, and 8.6 ± 1.4% and 8.7 ± 1.5% before and after the second episode. There were no major adverse events. Skin haematomas with a diameter of 0.5 to 4 cm were occasionally observed in five patients. In retrospect, it had coincided with LMWH treatment. A small but significant rise of hepatic transaminases was observed during LMWH treatment. No significant changes of haematological parameters were observed. Platelet counts remained constant: 257 ±53 (10 9 /l) and 277 ±72 (10 9 /l) before and after placebo and 281 ±44 (10 9 /l) vs 264 ±38 (101) before and after LMWH treatment.
Treatment
The medication for one treatment period was delivered as prefilled syringes containing a clear solution with either placebo or 40 mg/0.4 ml enoxaparin, corresponding with approximately 4000 aXa IU (kindly provided by RhonePoulenc Rorer B.V., Amstelveen, The Netherlands). The patients were educated to self-administer the medication subcutaneously in an abdominal skinfold before the night. They were instructed not to inject protamine-containing insulin preparations at the same site.
Renal function and blood pressure
RPF, GFR, and filtration fraction (FF) are listed in Table 1 . No statistically significant differences were observed for RPF and GFR during placebo or LMWH treatment. Furthermore, FF was very constant throughout the study. No differences were observed when FF before and after LMWH treatment were compared. Systolic, diastolic and mean arterial pressure did not change during placebo or LMWH treatment.
Laboratory assessments
AER was assessed using immunonephelometry on an autoanalyser (Array Protein system, Beckman Instruments Inc., Brea, Ca 92621-6209, USA) with specific antibodies. GFR and RPF were assessed using primed continuous infusion with 125 I-thalamate and 131 I-hippuran as previously described [16] . Glucose was assessed using the hexokinase method on a BM/Hitachi 747 autoanalyser (Boehringer Mannheim GmbH Biochemica, 6800 Mannheim 31, Germany). HbAlc was assessed on HPLC after haemolysis. Serum creatinine, urea, sodium, potassium, total protein, albumin, bilirubin, SGOT, and SGPT levels were analysed on a Dimension autoanalyser (Dupont, Wilmington, DE, USA). Haematological parameters were assessed using the Technicon H-l system (Bayer Diagnostics GmbH, 81539 Mflnchen, Germany).
Albumin excretion rate
AER of all patients are shown in Figure 1 . Baseline AER was similar for the two treatment periods, suggesting the crossover period had been of sufficient duration. AER was 447 (181-1102) ug/min at baseline before LMWH treatment. During LMWH treatment, AER reduced to 295 (100-873) ug/min (/><0.05). No changes of AER were observed after treatment with placebo (baseline: 397 (141-1117) ug/min compared to 336 (104-1081) ug/min). Compared to placebo the effect of LMWH treatment did not reach statistical significance after 1 month treatment in these six patients. Log transformation the data were analysed using a paired t test, which allowed us to quantify the effect of treatment and the difference between placebo and LMWH. AER decreased with 0.073 ±0.187 J. T. Tamsma el al. (6) 107 (7) 451 (105) 108 (26) (17) 81 (12) 109 (11) 414 (101) 94 ( 
Discussion
This paper reports preliminary results on the treatment of overt diabetic nephropathy with low-molecularweight heparin. Before we conducted this study, no data were available regarding dose, duration, potential effect and safety of LMWH treatment in patients with overt nephropathy. The rationale for this study was based on reports [9, 10] describing a decreased expression of heparan sulphate in kidneys of patients with overt diabetic nephropathy. Furthermore, LMWH treatment seemed to prevent diabetic nephropathy in rats [14] , and halted progression of mesangial sclerosis in several experimental kidney diseases [12, 13] . Recently a significant reduction of urinary albumin excretion rate was observed in diabetic patients with incipient nephropathy after treatment with LMWH [15] .
In this study we examined patients with overt diabetic nephropathy. We observed a significant decrease of AER during LMWH treatment which was not observed during placebo treatment. However, the comparison with placebo did not reach statistical significance. This may have been due to the small group size, the short period of treatment, or the considerable dayto-day variability of AER during the placebo treatment. We estimated that a sample size of 25 patients will be necessary to have 90% power (and a = 0.05) to detect a difference of -O.lOug/min if patients are treated for 1 month in a crossover design. Longer duration of follow-up may reduce the number of patients necessary. This can be illustrated by an example in which it is assumed that the difference would double during a 6-month treatment course to -0.20 ( io log ug/min). A sample size of eight patients would be sufficient to have 90% power to detect this difference with a level of significance of 0.05.
The mechanism leading to a decrease of AER during LMWH treatment is not clear. Theoretically a decreased AER may result from decreased intraglomerular pressure, from a decrease of capillary filtration surface, or from changes of the filtration barrier characteristics. Assuming filtration fraction is a reflection of intraglomerular pressure, the observation of an unaltered FF after LMWH treatment suggests that the antialbuminuric mechanism is not primarily pressure mediated. Alternatively a decrease of AER may suggest a change of capillary membrane characteristics. An accumulation of negative charge in the GBM could be a structural modification, leading to an decreased albumin filtration. It should be appreciated that the perspectives for long-term treatment will depend on effects of LMWH and related sulphated glycosaminoglycans on mesangial expansion [17] . In several experimental studies, LMWH treatment had an favourable effect on growth factor expression of mesangial cells and on mesangial matrix production [1, 12, 13] . In experimental diabetes, glycosaminoglycan administration modified renal matrix composition, one of the mechanisms being normalization of collagen gene expression [18] . However, these observations have not yet been reproduced in man, and will require longterm treatment trials.
A drawback to long-term administration of heparin will be the occurrence of side-effects. We observed a small but significant increase of hepatic transaminases during LMWH treatment, which necessitates monitoring liver enzymes during future trails. A well-known side-effect of long-term heparin administration is osteoporosis. Furthermore, the anticoagulant potential of LMWH is well recognized. Accurate diagnosis and follow-up of diabetic retinopathy therefore seems appropriate in these patients. The anticoagulant potential of heparin is known to be dependent on the degree and location of O-sulphation of the glycosaminoglycan chain. Sulphation of this particular place in the molecule is not of importance for the effects of sulphated glycosaminoglycans on mesangial cells [1] . Development of sulphated glycosaminoglycans without O-sulphated groups may provide a solution regarding the risk of treatment with sulphated glycosaminoglycans, especially in patients with proliferative retinopathy.
In summary, we observed a favourable effect of LMWH on AER in diabetic patients with overt nephropathy. One of the mechanisms of this effect may be a change in characteristics of the filtration barrier. These data suggest that long-term treatment trials with sulphated glycosaminoglycans in a larger group of patients may potentially demonstrate a new therapeutic option for patients with overt diabetic nephropathy.
